[Survival analysis on XXXX patients undergoing antiretroviral treatment, Liangshan prefecture, Sichuan province].

@entity1 @entity404 @entity645 @entity791 @entity204 @entity1907
OBJECTIVE: To analyze the survival time and its impact factors among @entity791 @entity1 who initially received antiretroviral treatment (ART) in Liangshan prefecture during 2004-2012. METHODS: A retrospective cohort study was conducted to analyze the information of @entity791 @entity1 who initially received ART. Data on @entity1 was collected from the Chinese @entity791 Antiretroviral Therapy DATAFax Information System. Life table was applied to calculate the survival proportion, and Cox proportion hazard regression model was used to identify impact factors that were related to the time of survival. RESULTS: Among 5 525 @entity791 @entity1 who initially received ART, the median age was (34.5   9.0) year old, with 73.9% being males, 65.8% were infected through injecting drug use, time from @entity645 tested @entity645 positive to starting ART was (23.0  20.1) months. 287 cases died of @entity791 , and their median time of receiving ART was (12.7  10.6) months, and 32.8% of them died within the first 6 months of treatment. Cumulative survival rates of the @entity1 who had received ART in 1, 2, 3, 4, 5 years were 97%, 93%, 89%, 88%, 84%, respectively. Results from multivariate Cox regression showed that female @entity1 who received ART were at a lower risk to the @entity204 of @entity791 (HR = 0.556, 95%CI:0.367-0.872), when compared to the males. @entity1 infected with @entity645 through injecting drug use were at a higher risk to @entity204 (HR = 1.569, 95% CI:1.061-2.321) when compared to those who were infected through heterosexual transmission. @entity1 with baseline @entity404 (+) T cells counts at <50 cells/mm(3) (HR = 11.996, 95% CI: 6.714-21.435) or 50-200 cells/mm(3) (HR = 2.481, 95%CI:1.620-3.798) were at a higher risk to @entity204 than those with @entity404 (+)T cell counts >= 350 cells/mm(3). @entity1 without @entity1907 were at a lower risk to @entity204 (HR = 0.511, 95% CI:0.330-0.791)when compared to those with @entity1907 a year before starting the treatment. CONCLUSION: Antiretroviral treatment could prolong the survival time of @entity791 @entity1 and with a better rate on survival. Programs on follow-up and @entity404 (+)T cell counts for @entity791 @entity1 should be conducted regularly, as well as timely initiated the antiretroviral therapy.
